BioSyent (CVE:RX) Share Price Passes Above 50-Day Moving Average – Here’s Why

BioSyent Inc. (CVE:RX) shares passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$10.61 and traded as high as C$11.48. BioSyent shares last traded at C$11.18, with a volume of 3,010 shares changing hands.

BioSyent Stock Up 5.5 %

The company has a market capitalization of C$129.58 million, a P/E ratio of 18.63 and a beta of 0.93. The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19. The stock has a 50 day moving average price of C$10.61 and a 200 day moving average price of C$9.72.

BioSyent (CVE:RX) last announced its earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, hitting the consensus estimate of C$0.13. The business had revenue of C$8.95 million during the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. On average, research analysts anticipate that BioSyent Inc. will post 0.6944444 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider FAX Capital Corp. sold 500,000 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of C$10.05, for a total transaction of C$5,025,000.00. In other BioSyent news, insider FAX Capital Corp. sold 500,000 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of C$10.05, for a total transaction of C$5,025,000.00. Also, Director Seyed Ahmad Ashrafi sold 2,320 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of C$10.95, for a total value of C$25,404.00. Insiders sold a total of 502,920 shares of company stock valued at $5,057,064 in the last three months. Insiders own 33.65% of the company’s stock.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.